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PERSPECTIVES IN CLINICAL NEPHROLOGY
Chemokines and renal disease
What determines the type of cellular infiltrate in tissue injury?
During the last 100 years pathologists have noted that etiolog-
ically different and specific types of inflammatory reactions are
associated with infiltration by specific subsets of inflammatory
cells. Recent experimental and clinical observations in various
forms of kidney diseases have highlighted the importance of
interactions of specific leukocyte populations such as neutrophils,
monocytes/macrophages and T cells with local renal cells in the
disease process (for this review leukocytes are defined as any type
of white blood cell) [1]. These studies also demonstrate how the
recruitment of specific inflammatory cells to sites of renal injury
contributes to both the acute and chronic phase of the specific
disease. Conditions that determine the type of cellular infiltrate at
the site of injury include: (1.) the local production and release of
chemotactic factors; and (2.) activation of inflammatory cells,
endothelium and surrounding cells resulting in the expression of
adhesion molecules such as selectins and integrins on both the
infiltrating inflammatory cells and the local cells.
Previously, several general chemotactic factors have been iden-
tified. These included the complement split product C5a, the
formyl methionyl peptides (fMLP), leukotriene B4 and platelet
activating factor (PAF). While these factors play a substantial role
in inflammatory reactions they lack a leukocyte cell-type specific-
ity. The enigma of leukocyte subtype specificity was resolved by
the discovery of the superfamily of chemotactic cytokines, named
chemokines, where each chemokine exhibits a rather restricted
and selective pattern of leukocyte attraction [2, 31. It is important
to stress that chemokines are generated and released locally and
are destined for local action. Chemokines appear not to be
designed to function systemically, as their systemic administration
or general overexpression in transgenic mice will not always lead
to the expected phenotypic effects [4].
Thus far, numerous experimental studies and tissue evaluation
of patients with a variety of inflammatory diseases of various
organs including the kidney support an important role for chemo-
kines in the specific type of leukocyte infiltration [3, 5].
The recent suggestion that chemokines may contribute to slow
progression of the HIV infection and the very recent identification
of chemokine receptors as docking molecules for HIV infection
obviously add tremendous excitement and significance to chemo-
kine research [6—8].
The chemokine family
Chemokines represent a large family of structurally related
chemotactic cytokines produced by a variety of immune and
nonimmune cells [2, 3]. They are secreted proteins of 8 to 10 kDa
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molecular weight selectively targeting different leukocyte sub-
populations. The complexity of this family is extensive as over 20
distinct human chemokines have been identified to date (Table 1).
The chemokine superfamily was originally divided into the C-C
and the C-X-C subfamily, which both contain four conserved
cysteine residues. In C-C chemokines the first two cysteines are
located adjacent to each other, whereas in the C-X-C family, an
additional amino acid is interspersed between them. Most C-X-C
chemokines are chemoattractants for neutrophils and have no
effect on monocytes, whereas C-C chemokines appear to attract
mainly monocytes, T cells, natural killer cells, and some granulo-
cytes but no neutrophils. Within the C-X-C family, the majority of
the proteins contain at the amino terminal region the amino acid
motif E-L-R-C-X-C (glutamic acid-leucine-arginine-cysteine-X-
cysteine). Most of these E-L-R-C-X-C chemokines are neutrophil
chemoattractants. In contrast, the three C-X-C proteins IP-lO,
PF4 and Mig, which lack the E-L-R motif, show a different
chemotactic spectrum of activities and do bind to different
receptor(s). However, after insertion of the E-L-R motif at the
amino terminus, PF4 becomes a neutrophil chemoattractant [9].
In this regard, the C-X-C chemokine family is thought to have at
least two branches [10]. Recently, a new chemokine has been
isolated that belongs neither to the C-C nor the C-X-C subfamily.
This protein was named lymphotactin and it represents the first
and as yet only member of a new third subfamily called the C
chemokines [11]. Lymphotactin lacks two of the four conserved C
residues and functions as a potent chemoattractant for T lympho-
cytes, but does not attract monocytes or neutrophils.
General chemokine function
To understand the biological significance of the chemokines,
one must view them in the broader context of leukocyte-endothe-
hal-cellular matrix interactions [12]. The migration of leukocytes
from the peripheral circulation into interstitial spaces involves a
series of complex interactions between molecules expressed on
the leukocyte, the endothelial surface and the extracellular matrix.
The process of leukocyte trafficking has been modeled into
discrete stages (Fig. 1). The initial stage involves rolling of
leukocytes along the microvascular vessel wall through transient
interactions between specific selectin proteins and their carbohy-
drate ligands. The next stage involves activation of the leukocyte
resulting in a firm adhesion to the endothelial surface mediated
through integrin molecules. The final stage involves extravasation
of the leukocyte, which includes crawling along the endothelium,
diapedesis, and migration into the interstitial spaces [12].
Chemokines are thought to play a role at pivotal stages in this
process: First, chemokines, produced at the site of injury or
released by activated platelets, are sequestered in solid phase on
the endothelial cell surface (immobilized via electrostatic interac-
tions with negatively charged glucosaminoglycans or presented by
distinct structures). Here they act as sign posts for specific types of
leukocytes as the circulating cell rolls along the endothelial
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surface [121. These surface bound chemokines can cause activa-
tion of leukocytes resulting in the up-regulation of integrins, an
arrest of rolling, and firm adhesion of the leukocyte to the
endothelial surface. Next, the leukocyte can crawl along a surface
bound chemotactic gradient formed by chemokines through a
process known as haptotaxis [13, 14] or follow a local solute
gradient of chemokines [15]. Finally, at some point the leukocyte
extravasates through the endothelium and basement membrane
into the tissue space, presumably while still responding to a
chemotactic/haptotactic chemokine gradient. In this context it is
of special interest that chemokines have also been demonstrated
to up-regulate the secretion and activity of matrix metalloprotein-
ases by infiltrating leukocytes [16]. The activation of these en-
zymes are thought to facilitate leukocyte transmigration through
the basement membrane and extracellular matrix [17].
Chemokines can also activate cells that they attract. IL-8
induces ncutrophil granule release [18] and the respiratory burst
[19]. RANTES will cause basophil and eosinophil degranula-
tion and respiratory burst in eosinophils [20, 21]. In addition,
RANTES has been shown to function as a co-stimulatory agent
in T cell proliferation [221. In a broad context, each of these
functions can be viewed as part of the inflammatory process in
which chemokines appear to play a central role.
Once the specific leukocyte has reached the point of highest
chemokine concentration, it will remain there and secrete cyto-
kines and additional chemokines resulting in a local amplification
loop and further leukocyte accumulation. At this stage the
leukocyte may become the major source of chemokines. The
leukocyte accumulation will result in the removal of the initiating
insult (such as phagocytosis of bacteria, immune complexes, etc.)
and eventual repair of the tissue. The inactivation and removal of
the inflammatory cells once their goal has been accomplished is
also important, as otherwise a chronic inflammation with progres-
sive tissue destruction and sclerosis will ensue. Factors governing
the termination of the inflammatory response could involve ligand
mediated down-regulation of chemokine and cytokine synthesis or
chemokine receptors by local factors (such as prostaglandins,
TGF-13) or a specific combination of inflammatory mediators
leading to local apoptosis of the involved leukocytes [23].
Chemokines also display broader biological functions. For
example, some chemokines appear to have roles in hematopoiesis
[24]. The MGSA/GROa C-X-C chemokine was originally identi-
fled as an autocrine growth factor for a human melanoma cell line
[25]. IL-8 is a potent angiogenic factor [26]. PF4 has been shown
to inhibit tumor growth, probably through anti-angiogenesis prop-
erties, and to inhibit megakaryopoiesis [27]. PF4 has also been
shown to reverse Con-A induced immune suppression in mice
[28]. Finally, PF4 has also demonstrated bactericidal functions
[29]. Further study of the general effects of chemokine expression
on angiogenesis and issues of tissue remodeling should prove
interesting in the future.
Recently it has been shown that RANTES, MIP-ics and
MIP-113 produced by CD8 T cells dramatically inhibit the
replication of HIV in vitro. It has been speculated that the
production of these chemokines by CD8 T cells is at least in part
responsible for the phenomenon of the "slow progressor" pheno-
types seen in some HIV infected individuals [30]. This hypothesis
is further supported by the very recent identification of chemokine
receptors as necessary cofactors for HIV infection of leukocytes
[6—8].
Chemokine genes
The genomic organization and chromosomal localization for
many of the C-X-C and C-C chemokine genes has been described
in recent reviews [2, 3]. All of the C-C genes have been mapped
to human chromosome 17 (qll-21) and to a syntenic region of
chromosome 11 in the mouse. The C-X-C chemokines likewise
are located as a gene cluster on human chromosome 4 (q12-q21)
and chromosome 5 in the mouse. The C chemokine lymphotactin
has been localized to chromosome 1 in humans as well as in the
mouse [11]. The C-C chemokine genes show a three exon, two
intron organization. The C-X-C genes with the exception of PF4
and the PBP genes appear to have a four exon, three intron
structure. PF4 and the PBP genes show a three exon, two intron
configuration as found in the C-C chemokines.
Chemokines can be rapidly up-regulated upon activation of
cells. Detailed studies of the transcriptional regulation have been
performed for only some of the chemokines, including IL-8,
MCP-1 and RANTES. Members of the NF-KB/ReI family, C/EBP
family, and the AP-i family of transcription factors appear to play
a prominent role in the regulation of these chemokine genes
[31—34]. The 5'-flanking sequences of the C-X-C chemokines
GROa, GROf3 and GROy contain binding motifs for NF-KB [2].
Many of the chemokines are also regulated post-transcriptionally
and often contain an AUUUA element in their 3' untranslated
region, which is thought to be involved in mRNA destabilization
[35, 36].
Table 1. The human chemokine superfamily
C-X-C cheniokines
IL-8
GROa
GROI3
GROY
ENA-78
PF4
'P-b
GCP-2
Mig
SDF-lcs
SDF- 1f3
PBP
PBP cleavage
products:
CTAB-III
/3-TG
NAP-2
C-C chemokines
MCP-l
MCP-2
MCP-3
MCP-4
RANTES
MIP-lo
MIP-113
I-309
Eotaxin
HCC-1
C chemokines
Ltn Lymphotactin
Leukocyte rolling
Firm adhesion Extravasation
"sap
Endothelium
Epithelial cells
.\ 1.Chemokines •
• • • ••••
•
•
a
Basement membrane
Inflammatory
leukocytes
• •
.•'
Interstitial cells
or
mesangial cells
612 Schlondo,ff et a!: hemokines and renal disease
Fig. 1. Schematic representation of the Current model of chemokine involvement in leukocyte trafficking. For details see text.
Secretion and matrix binding
Chemokine mRNAs contain leader signal sequences that direct
the protein to the endoplasmic reticulum and eventually to
secretory vesicles. In most cell types, such as endothelial cells,
vascular smooth muscle cells, mesangial cells and fibroblasts,
chemokines are generated de novo and secreted upon stimulation.
Platelets, however, can release preformed chemokines upon acti-
vation [37].
Most chemokines readily dimerize in solution and undergo
oligomerization at high concentrations of protein and at neutral
pH. Nevertheless, some chemokines can function as monomers
[38, 39]. Chemokines are basic proteins and will bind to heparan
sulfate proteoglycans on cell surfaces, or the extracellular matrix,
which may be important for the activation and in the haptotactic
process as leukocytes migrate from the endothelium and through
the interstitium.
Chemokine receptors
The biological effects of the chemokines appear to be mediated
through interactions with seven-transmembrane, G-protein cou-
pled receptors [40]. Chemokine concentrations required for re-
ceptor binding and cell activation are in the nanomolar range. The
chemokine receptor genes are expressed in a cell-type specific
manner and this differential expression may be the basis for the
specificity of chemokines for subsets of leukocytes. The charac-
terized human chemokine receptors (as of June 1996) are listed in
Table 2. During a recent meeting on chemokines, a new nomen-
clature for the receptors has been agreed upon (Tom Schall,
personal communication). In Table 2 the new nomenclature is
provided and the previous names are given in parentheses.
Binding of a given chemokine to its receptor(s) leads to
activation of phospholipase C f31 and 2, production of inositol
(1,4,5)-trisphosphate and diacyiglycerol, a rapid and transient
increase in intracellular calcium and the activation of PKC. Many
details are still unclear, hut it seems that chemokines can activate
Table 2. Human chemokine receptors
Receptor Ligand Expressing cells
CXCR-1 (IL-8RA) IL-8 N, M, T, NK, Ba
CXCR-2 (IL-8RB) IL-8 and other N, M, T, NK
E-L-R-C-X-C chemokines
CCR-1 (CC CKR-1) MIP-la, RANTES, MCP-3 M, T, NK, B, (N, E)
CCR-2 (CC CKR-2) MCP-1, MCP-3 M
CCR-3 (CC CKR-3) eotaxin, RANTES, MCP-3 E, (M, N)
CCR-4 (CC CKR-4) MIP-la, RANTES, MCP-1 Ba, M, T, B, P
CCR-5 (CC CKR-5) MIP-la, RANTES, MIP-1/3 Ma
DARC (=ECKR) many C-X-C and C-C RBC, endothelial
chemokines cells (kidney),
brain
Abbreviations
IL-8RA, IL-8RB Interleukin 8 receptor type A or B
CXCR-1,2 CXC chemokine receptor (new nomenclature)
CC CKR-1, 2, 3, 4, 5 C-C chemokine receptor (old nomenclature)
CCR-1, 2, 3, 4, 5 CC chemokine receptor (new nomenclature)
DARC Duffy antigen receptor for chemokines
ECKR Erythrocyte chemokine receptor
N, E, Ba Ncutrophil, eosinophil, basophil granulocytcs
M, T, B Monocytes, T lymphocytes, B lymphocytes
Ma Macrophages
NK Natural killer cclls
P Platelets
RBC red blood cells
both G protein dependent and independent signal transduction
pathways. Different kinases may be involved in signal transduc-
tion, including serine/threonine kinases (such as members of the
MAP kinase cascade) as well as tyrosine protein kinases [41].
The known chemokine receptors can be grouped into four
different classes, namely the "shared," "specific," "promiscuous"
and "virally encoded" receptors [10]. The shared receptors bind
Mesangial TNF-a
cells IL-1/3
LPS
PMA
IgG
IFN-y
PDGF
Epithelial TNF-a
cells IL-1p
LPS
JFN-y
IL-la
Endothelial TNF-a
cells IL-I13
PMA
Interstitial
cells
DMTU
TMTU
PDTC
NAC
HMAP
cAMP
PGE2
dcx
genistein
herbimycin
tyrphostin
TPCK
TNF-a
IL-I (3
TNF-a
IL-I/I
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Table 3. Chemokines produced by kidney cells
DMTU
TMTU
PDTC
NAC
HMAP
cAMP
PGE2
dcx
TNF-a
IL-1J3
LPS
TNF-a
IL-I/I
TNF-a
IL-I/I
TNF-a
IL-i/I
Symbols are: +, up-regulation; —, inhibition.
more than one chemokine within either the C-X-C or the C-C
subfamily. The IL-8 receptor type B (CXCR-2), which binds
C-X-C chemokines containing the E-L-R motif as well as the CC
chemokine receptors CCR-1 to CCR-5, belong to this class [42,
43]. The "shared" CCR-1 to -5 receptors have recently become a
major focus of HIV research as they appear to be co-factors for
the infection of CD4 cells with HIV [44—46]. The "specific"
receptors bind only one chemokine. So far the IL-8 receptor type
A (CXCR-1) represents the only example of this class [47]. The
third type, or promiscuous chemokine receptor, binds both C-X-C
and C-C chemokines and it is found on the surface of erythrocytes
[48]. This so-called Duffy antigen receptor for chemokines
(DARC) is the recognition structure for the malarial parasite
Plasmodium vivw. [49]. DARC is also found on the endothelium
of postcapillary venules in many organs including the kidney [50].
It is thought that the erythroid expressed DARC may act as a
means of clearing chemokine from the circulation to prevent these
agents from acting systemically. The DARC found on postcapil-
lary venules may be involved in presentation of chemokines on the
endothelial surface. The fourth type of chemokine receptor has
been found to be encoded within viral genomes [45, 51]. The
virally encoded chemokine receptors exhibit superior binding and
signaling properties relative to the human receptor analogues.
The role of these receptors in viral pathogenesis is at present
unclear.
Little is known about the effect of chemokines on protein
expression in target cells. So far, only adhesion molecules and
cytokines have been analyzed. MCP-1 can induce the expression
of /3-2 integrins and the production of interleukin 1 and interleu-
kin 6 in human monocytes [52]. In another study, MCP-1, MIP-lcx
and RANTES were shown to increase the expression of the /3-2
integrins CD11b/CD18 and CD11c/CD18, but had no effect on
CD11a [531.
Expression of C-C chemokines in renal cells
Before reviewing the in vivo expression of chemokines in renal
tissue and renal disease we will summarize their production by
specific renal cells in vitro (Table 3). The expression of the MCP-1
gene has been studied intensively in renal tissues and was recently
reviewed [54]. MCP-1 can be induced in cultured mesangial,
tubular epithelial and endothelial cells. These experiments were
performed using primary cell cultures and some transformed cell
lines.
In cultured mesangial cells MCP-1 is up-regulated in a dose-
dependent manner by stimulation with tumor necrosis factor-
alpha (TNF-a) [551, interferon-gamma (IFN-y) [56, 57], interleu-
kin- ibeta (IL-I/3) [58], platelet-derived growth factors PDGF-AB
and PDGF-BB [59], lipopolysaccharide (LPS) [60], or phorbol
myristate acetate (PMA). Co-stimulation with PDGF and IL-1f3
shows a synergistic effect [59]. MCP-1 expression is also induced
by immunoglobulin G (IgG) complexes, an effect mediated
through the immunoglobulin-Fe receptor [61]. In general, the
up-regulation of MCP-I occurs rapidly, peaks after two to six
hours and returns within 24 hours to baseline. While transcrip-
tional regulation of MCP-1 is important to the up-regulation of
this gene, post-transcriptional regulation through alterations in
mRNA stability may also occur [62].
In human renal cortical epithelial cells expression of MCP-1 can
be up-regulated by IL-1/3 and IFN-y and to a lesser extent by
TNF-cs and LPS. Maximal levels of mRNA were found six hours
after stimulation, and MCP-1 protein was detected after 8 to 12
hours [631. Similarly, human proximal tubular epithelial cells also
express MCP-I following stimulation by IL-Ia and TNF-a in a
time- and dose-dependent manner [64]. Endothelial cells cultured
from bovine glomeruli were found to constitutively express
MCP-l RANTES ENA-78 GROa GRO/3 IL-8
+ + — + + — + — +
genistein TNF-a
IL-i/I
LPS
TNF-a
IL-i /3
LPS
TNF-/3
IgG
IFN-y
TN F-a
IL-i/I
IL-la
genistein TNF-a dcx
IL-I /3
IL-la
TNF-a
IL-i/I
LPS
IL-i/I TNF-a
IL-i/I
LPS
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MCP-1 mRNA. Levels of MCP-1 mRNA could be increased by
stimulation with TNF-a, IL-1f3 or PMA [65].
The chemokine RANTES is expressed by mesangial cells,
tubular epithelium and fibroblasts following stimulation with
TNF-s, IL-1f3, LPS or TNF-/3 [66]. The induction of RANTES by
TNF-a and IL-i /3 is augmented by co-stimulation with IFN-y [67J.
IgG complexes can also up-regulate RANTES [68]. In rat derived
tubular epithelial cells RANTES expression is induced by TNF-a
and IL-la [69]. In mouse mesangial cells RANTES mRNA was
detected two hours after stimulation with TNF-a and levels
peaked by 24 hours [70].
Expression of C-X-C chemokines in renal cells
IL-8 is produced in mesangial, epithelial and endothelial cells as
well as in renal flbroblasts following stimulation with TNF-a and
IL-113 (Table 3) [71]. Pretreatment of the mesangial cells with
dexamethasone resulted in a reduced induction of IL-8 [72].
Stimulation of human renal cortical epithelial cells with TNF-a,
LPS or IL-1p enhanced expression of IL-8, whereas IFN-y had no
effect [63].
The expression of ENA-78 has so far only been demonstrated
for human renal tubular epithelial cells. Increased expression was
found after stimulation with IL-1/3. Surprisingly, neither TNF-a,
IFN-y nor LPS showed any effect [73].
The chemokines CINC and MIP-2, rat homologues of human
GROa and GROI3 respectively, are produced by mesangial and
epithelial cells in response to stimulation with TNF-a, IL-I /3 and
LPS [12]. The cytokine TGF-beta failed to stimulate CINC and
MIP-2 expression. In rat mesangial cells the up-regulation of
CINC and MIP-2 could be attenuated by the tyrosine kinase
inhibitor genistein [74].
Second messengers involved in chemokine gene regulation
The second messengers involved in chemokine expression by
renal cells have been studied by several groups. Reactive oxygen
species (ROS) have been implicated as second messenger inter-
mediates for TNF-a and IgG induced stimulation. Radical scav-
engers such as di- and tetramethylthiourea (DMTU and TMTU),
pyrrolidone-dithiocarbamate (PDTC) or N-acetyl cysteine (NAC)
attenuate TNF-a or IgG induced up-regulation of MCP-1 and
RANTES [68, 75]. Generation of superoxide anions by exoge-
nous xanthine oxidase and hypoxanthin increases MCP-1 and
RANTES mRNA levels. TNF-a, IL-1/3 and IgG complexes can
activate a membrane-bound NADPH-oxidase resulting in super-
oxide generation, which may up-regulate MCP-1 expression.
Consistent with this hypothesis is the finding that inhibition of the
NADPH-dependent oxidasc causes attenuation of MCP-1 and
RANTES expression in response to stimulation by TNF-a or IgG
[68, 75].
An increase in intracellular levels of cAMP will inhibit expres-
sion of some cytokines [76]. In mesangials cells the expression of
MCP-1 and RANTES is also attenuated by agents known to
increase levels of cAMP such as PGE2, forskolin or phosphodi-
esterase inhibitors [56].
In bovine glomerular endothelial cells the induction of MCP-1
expression seen with TNF-a or IL-1/3 could be inhibited by
addition of the protein tyrosine kinase (PTK) inhibitor genistein.
The protein kinase C (PKC) inhibitors staurosporine and H7 and
the protein kinase A (PKA) inhibitor H-89 show no effect.
Stimulation with PMA, which acts as an protein kinase C activa-
tor, was only suppressed by protein kinase C inhibitors [65].
Similarly, in human mesangial cells the PTK inhibitors genistein,
herbimycin A and tyrphostin cause a dose-dependent inhibition of
MCP-1 expression in response to IL-1J3 induction, whereas PKC
or PKA inhibitors show no effect [77].
The transcription factor NF-KB appears to play a major role in
control of chemokine gene expression. Recently, the activation of
NF-KB in mesangial cells has been examined. Stimulation with
TNF-a and IgG complexes causes an increase in nuclear NF-KB
[78]. The radical scavenger PDTC and the inhibitor of the
NADPH-dependent oxidase HMAP attenuated the increase in
nuclear NF-KB in response to TNF-a or IgG complexes, suggest-
ing a potential role for ROS in the activation of NF-KB. This is
further supported by the observation that generation of superox-
ide anions by xanthine oxidase and hypoxanthine increased nu-
clear NF-KB and MCP-1 expression. This effect could be inhibited
by increasing intracellular cAMP levels with PGE2, forskolin or 8
Br-cAMP [56, 78]. These results could be explained by assuming
that stimulation of mesangial cells with TNF-a or IgG complexes
leads to generation of ROS which enhance chemokine gene
expression by activation of NF-KB. The activation of NF-KB and
chemokine expression may be down-regulated by raising intracel-
lular cAMP levels which may represent an important feedback
loop. Similarly, IL-i leads to an activation and nuclear transloca-
tion of NF-KB that correlated with increased transcription of
MCP-1. Activation of NF-KB is prevented by the inhibitory
component of NF-KB, that is, 1KB. When proteolytic inactivation
of 1KB is prevented by the protease inhibitor tosyl-phe-chioro-
methylketone (TPCK) NF-KB cannot be activated, and this also
inhibits MCP-1 expression [79]. These results further support a
role for NF-KB in chemokine expression. The inhibitory effect of
dexamethasone on chemokine expression may also be mediated
by interference with NF-KB activation [801. In other systems
dexamethasone has been shown to both increase 1KB levels and to
decrease NF-KB activity in the nucleus [81]. In the future,
therapeutic considerations on inhibitory actions of prostaglandins
and glucocorticoids will obviously be of great interest.
Expression of chemokines in animal models of kidney diseases
The investigation of chemokine involvement in renal diseases
represents a logical step as different types of leukocytes play major
roles in acute and chronic renal injury. So far the C-C chemokines
MCP-1, MIP-la, MIP-1f3, and RANTES and the C-X-C chemo-
kines GROa, GROI3, IL-8, IP-lO and PF-4 have been examined in
animal models.
The anti-thymocyte antiserum (anti-Thy 1.1) induced model of
glomerulonephritis in rat is characterized by a complement-
dependent, initial mesangiolysis, followed by a mesangial prolif-
erative glomerulonephritis with an increase of extracellular ma-
trix, and finally a healing phase. MCP-1 expression in glomeruli
was found to be markedly up-regulated as early as 30 minutes
after induction of the disease. The immunofliiorescence staining
of MCP-1 protein revealed a predominant mesangial pattern and
some staining in the peritubular capillaries. Concomitantly an
increase of glomerular monocyte/macrophage infiltration could
be seen. Complement depletion largely prevented the glomerular
lesions, as well as the expression of MCP-1, and influx of
mononuclear cells into the glomeruli. The findings are consistent
with complement-mediated injury by Thy 1.1 antiserum resulting in
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early increase of MCP-1 expression and infiltration with mono-
cytes/macrophages [82]. Parallel to the in vitro experiments with
PGE2 supression of chemokine generation, pretreatment of rats
with PGE2 also decreased glomerular MCP-1 expression and
disease activity [83].
The isolated perfused kidney model allows exclusion of circu-
lating leukocytes as a source of chemokines. In this model
perfusion with LPS caused MCP-l expression especially in pen-
tubular capillary endothelial cells [841. Glomerular MCP-1 ex-
pression can also be stimulated in isolated perfused kidneys after
induction of anti-Thy 1.1 nephritis, an effect mitigated by an
antagonist of platelet-activating factor (PAF). Perfusion of iso-
lated kidneys with PAF alone increased glomerular MCP-1
mRNA levels as determined by RT-PCR. This suggests that PAF
may play a mediator role for the initial MCP-1 expression in the
anti-Thy 1.1 model of glomerulonephritis [85]. These intriguing
observations will need further confirmation and validation in vivo.
The role of IL-8 has been examined in a rabbit model of acute
immune complex-mediated glomerulonephritis by using chemo-
kine-neutralizing antibodies [71]. In this model, injection of
bovine serum albumin (BSA) lead to glomerular immune complex
deposition followed by neutrophil infiltration of the glomeruli and
proteinuria. In the glomeruli of control rabbits no IL-8 protein
was found by immunohistochemical staining whereas glomerular
IL-8 expression was seen in diseased glomeruli. Furthermore, in
the rabbits with proteinuria, urinary IL-8 levels were increased.
Administration of an neutralizing anti-IL-8 antibody decreased
neutrophil influx into the affected glomeruli by 40% and surpris-
ingly abrogated proteinuria completely [71].
Several groups have examined the model af anti-glomerular
basement membrane antibody induced glomerulonephritis (anti-
GBM GN) in the rat and mouse. Glomerular mRNA expression
of the C-X-C chemokines, CINC and MIP-2, was increased as
early as 30 minutes after induction of the disease. The first
increase in the PF4 or IP-lO mRNA level was found after three
hours [74, 86, 87]. The maximum expression was observed be-
tween three and six hours and was associated with an increased
influx of PMN [87]. Administration of specific antibodies to
neutralize CINC or MIP-2 reduced PMN influx into the glomeruli
by 40% and concomitantly decreased urinary protein excretion.
Complement depletion by cobra venom factor, depletion of
leukocytes by irradiation or depletion of PMNs by specific anti-
serum administration almost completely abrogated the expression
of CINC and MIP-2 [74]. A possible conclusion might be that in
a local amplification loop PMN contribute directly or indirectly
(such as via TNF- production) to further chemokine production.
In time course experiments MIP-113 mRNA could be detected
30 minutes after induction of the anti-GBM disease. After three
hours MIP-1 and MCP-3 mRNA levels were increased. MCP-1
mRNA expression peaked between 6 and 25 hours and persisted
up to 96 hours [87—89]. RANTES expression was not increased up
to 24 hours [87], but was found on day 3 in one study [88]. The
expression of C-C chemokines was associated with mononuclear
influx into the diseased kidney. Administration of dexamethasone
to rats with anti-GBM nephritis lead to a 50% reduction of
glomerular PMN influx and the mononuclear infiltration was
nearly completely inhibited. Concomitantly, the glomerular
mRNA expression for MIP-2 was decreased by 60% and that for
MCP-1 by up to 98% [87]. Renal expression of MCP-1 and
RANTES mRNA was also observed in a murine model of
0
Time, hours
Induction of glomerulonephritis
Fig. 2. Time course of chemokine mRNA levels and leukocyte infiltration in
an animal model of anti-GBM antibody-induced glomerulonephritis (based
on data from [87, 88]). Symbols are: (----) MIP-2; (—) PMN; (- — — -)
MCP-1; (———) monocytes.
anti-GBM nephritis in op/op mutant mice, which lack monocyte-
colony stimulating factor (CSF-1) and hence are severely macro-
phage deficient [90]. Therefore, macrophages could not be the
source for MCP-1 and RANTES in the mouse kidneys with
anti-GBM nephritis. These data provide initial support for a role
of chemokines in the leukocyte infiltration in experimental gb-
merulonephritis (Fig. 2).
Recently Tang, Qi and Warren reported in a preliminary study
that pretreatment of rats with a neutralizing anti-MCP-1 antibody
before inducing an anti-GBM nephritis resulted in an —50%
decrease in glomerular macrophage infitration and 40% reduction
of proteinuria [911. In contrast, another group could not influence
the course of a puromycin-induced nephrotic syndrome in rats by
the administration of an anti-MCP-1 antibody [92]. Further
investigations will be necessary to determine the role of specific
antibodies against chemokines in influencing experimental renal
diseases.
In a rat model of anti-tubular basement membrane tubuloin-
terstitial nephritis preliminary RNase protection data suggest an
early increase in CINC and MIP-2 expression that is associated
with neutrophil infiltration of the kidneys. MCP-1, MIP-1 and
MIP-1 13 were expressed later. These chemokines were localized to
the vicinity of infiltrating mononuclear cells in the renal cortex
[931
The expression of chcmokincs has also been studied in non-
immunological disease models. Bilateral renal hilar clamping for
50 minutes served as a rat model for acute ischemic renal failure.
KC mRNA, the homobogue of GROa, was rapidly detectable,
peaked after one hour and decreased to normal levels within 24
hours. JE/MCP-1 mRNA was up-regulated later and persisted 96
hours after inducing ischemia [94]. As ischemic renal failure is
also associated with leukocyte infiltration, these results support a
role of chemokines in ischemic injury and repair.
In the 2-kidney 1-clip hypertension rat model the "clipped"
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kidney represents a model for ischemic lesions, while the non-
clipped kidney can be used as a model for hypertensive damage.
Differences were found in the expression of chemokines. In the
clipped kidney elevated MCP-1 mRNA levels were found at day 2
and during the following 26 days. In the contralateral kidney, an
increase in MCP-1 mRNA was seen after 14 days and 28 days and
a monocyte/macrophage infiltration was present. The authors
suggested that MCP-1 may mediate ischemia and hypertension-
induced mononuclear cell infiltration [95].
Unilateral ureteral obstruction in rats as a model of hydrone-
phrosis results in renal cortical macrophage infiltration and later
interstitial fibrosis. The expression of MCP-1 mRNA was detected
after 12 hours and persisted for four days in the obstructed kidney.
Immunohistology revealed increased MCP-1 protein in the cortex.
The MCP-1 expression was associated with macrophage influx
into the obstructed kidney [96].
The various models of renal diseases support a role for chemo-
kines in leukocyte infiltration. The exact source of the chemokines
remains to be determined but could, depending on the models,
involve glomerular and tubular epithelial cells, glomerular and
peritubular endothelial cells, mesangial and interstitial cells. Fur-
thermore, the possible amplification of chemokine!cytokine ex-
pression by infiltrating inflammatory cells, such as PMN may
result in a further influx of monocyte/macrophages. The release of
chemokines from platelets may explain the detection of chemo-
kine protein by immunohistochemistiy in the absence of chemo-
kine mRNA. Future experiments will have to include more
detailed immunohistology, in situ hybridization, leukocyte and
thrombocyte depletion studies, and experiments with genetically
modified animals such as transgenic or knockout mice for specific
chemokines and their receptors. Thus far, data on MCP-1 trans-
genie mice [4, 97] and IL-8 receptor homologue knockout mice
[98] have been published. The IL-8 receptor homologue knockout
mice showed a surprising phenotype. The mice displayed sup-
posed inflammatory responses and migration of neutrophils, but
showed in addition a massive overproduction of neutrophils and B
cells. Transgenic mice overexpressing MCP-1 in the thymus and
the central nervous system were characterized by a higher number
of mononuclear cells in these tissues [97].
Chemokine expression in kidney biopsies
Glomerular diseases
Prodjosudjadi and colleagues have examined the expression of
MCP-1 by immunohistology in normal human kidneys and in 50
kidney biopsies with various diseases, including transplants [99].
The intensity and the distribution of the fluorescent signal corre-
lated with the local infiltration of macrophages. In control kid-
neys, a weak staining for MCP-1 was seen in tubular epithelial
cells, It is unclear if this represents nonspecific background
staining. A significant increase of glomerular staining was found in
membranous nephropathy. Surprisingly, strong tubular epithelial
staining was found in membranous nephropathy, IgA nephropa-
thy and glomerulosclerosis. It is possible that proximal tubular cell
protein and lipid overload secondary to the marked proteinuria
causes production of chemokines by tubular cells. In glomerulo-
sclerosis enhanced tubular MCP-1 staining was associated with an
increased number of infiltrating macrophages in the interstitium.
Surprisingly, MCP-1 expression was not found in transplant
rejection although a large number of infiltrating macrophages was
present. These authors also found no MCP-1 staining in extracap-
illary proliferative GN, membranoproliferative GN, lupus nephri-
tis and chronic ischemia although all these diseases are associated
with monocyte infiltration [64, 991 Wada and colleagues [100]
performed immunohistochemistiy and in Situ hybridization stud-
ies for MCP-1 in biopsies of SLE patients. MCP-1 was detected in
peritubular capillaries, in infiltrating monocytes and in cortical
tubular cells, but surprisingly not in glomeruli [100]. Different
results were obtained in another study [101]. Using immunohis-
tology, positive staining for MCP-1 was found in glomeruli from
biopsies of patients with proliferative GN, Wegeners disease and
lupus nephritis. The staining pattern was focal and seemed to have
a mesangial distribution. Negative staining was found in biopsies
of minimal change disease, membranous nephropathy, glomeru-
losclerosis or IgA nephropathy [1011.
Urinary and serum MCP-1 levels were evaluated in patients
with systemic lupus erythematodes [100, 102] and with various
forms of glomerular diseases [103]. In active lupus nephritis
urinary MCP-1 levels determined by ELISA were 10- to 20-fold
higher in comparison to patients with inactive disease or healthy
controls. A high urinary MCP-1 excretion strongly correlated with
leukocyte infiltration in the kidneys [1001. In lupus nephritis no
correlation was found between urinary MCP-1 levels and protein-
uria or serum MCP-1 levels. Treatment of the patients with high
doses of glucocorticoids signifcantly lowered urinary MCP-1
excretion and levels decreased to normal values in patients
undergoing remission. Rovin, Doe and Tan reported elevated
urinary MCP-1 levels in patients with a variety of glomerular
diseases [103]. Urinary MCP-1 correlated with the degree of
proteinuria, with the number of glomerular macrophages and with
the severity of disease. These data support a role or MCP-1 in the
macrophage infiltrate of various forms of nephritis.
At present, it appears difficult to reconcile the different immu-
nohistological patterns reported. This may be due to different
staining techniques and different sources of antibodies. These
discrepancies should be resolved by the exchange of antibodies
and tissues between the laboratories and by meticulous attention
to details for the handling of samples (such as time from biopsy to
tissue fixation). Ideally, expression studies should be comple-
mented by in situ hybridization. Finally, different results may
reflect the stage of the disease (such as acute vs. chronic,
secundary tubular and intersitial ivolvement) and the treatment
(such as glucocorticoids) that the patients may have received.
HIV nephropathy
Elevated tissue levels of RANTES, IL-8 and MCP-1 have been
reported in biopsies from patients with HIV nephropathy [104]. It
is interesting that HIV-associated nephropathy affects predomi-
nantly patients of Central African and African American lineage.
Most individuals from West and Central Africa are negative for
Duffy antigen, that is, they do not express DARC on the surface
of their red blood cells. This provides a selective advantage
because DARC serves as a receptor for the malarial parasite P.
vivax. As DARC may function as a clearance mechanism for
chemokines, it is speculated that chronic production of the
chemokines RANTES, MIP-1 a and MIP-lp during HIV infection
in the absence of clearance by DARC may result in accumulation
of the positively charged chemokines on the negatively charged
glomerular filtration barrier, resulting in a perturbation of the
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filtration function, leading to proteinuria and potentially to in-
flammation and mononuclear cell infiltrate. High circulating
levels of chemokines could also result in their binding to the
second form of DARC present on postcapillary venules of the
kidney (as this form of DARC is present in Dufl'y negative
individuals) and thus promote leukocyte "recruitment" to the
kidney. At present these are speculations that need to be tested
further.
Renal transplant rejection
Levels of RANTES and MIP-1/3 were found to be increased in
kidney transplant rejection using in situ hybridization and immu-
nohistochemistry [105, 106]. Both chemokines were found to be
expressed by infiltrating mononuclear cells, and by tubular epi-
thelium [105, 106]. In addition, RANTES protein was found on
the endothelium of peritubular capillaries, although no local
RANTES mRNA production could be detected by in situ hybrid-
ization. This suggests that RANTES had been bound to the
endothelial surfaces, potentially contributing to local T cell and
monocyte recruitment [14].
Chemokine expression during renal development
At least one chemokine, RANTES, appears to be expressed in
a regulated manner during human renal development [107].
RANTES protein is present in the glomerular mesangium and in
the proximal tubules. Interestingly, strong expression of RANTES
mRNA was found throughout the developing kidney even in areas
that were negative by immunohistology. These results indicate
both a developmental and translational control of RANTES ex-
pression in these tissues [107]. Although the function of RANTES
in kidney development remains to be determined, this finding
suggests a role for RANTES distinct from its role as a proinflam-
matory cytokine [107].
Wilms' tumor and renal cell carcinoma
The production of chemokines by tumor cells or tumor associ-
ated cells could explain in part the mononuclear cell infiltrate
surrounding these tumors. In biopsy samples Wilms' tumor was
found to express the RANTES chemokine [107]. The subcapsular
nephrogenic blastema and resident macrophages stained strongly
for RANTES protein. By contrast, only one in five renal cell
carcinomas was shown to express the RANTES chemokine.
However, in each renal cell carcinoma biopsy tested, infiltrating
mononuclear cells were found to express RANTES protein [107].
Conclusions, future directions and therapeutic outlook
Rcnal tissues produce both C-X-C and C-C chemokines in vivo
and in vitro in response to stimulation by agents such as: prom-
flammatory cytokines, immune complexes, complement activa-
tion, and hypoxia. The production of free radicals may represent
a common mediator for the activation of chemokines, which also
involves transcription factors of immediate early gene responses,
among which NF-KB appears to play a central role.
Based on the available data, a hypothetical model for the role
of chemokines in acute glomerular and tubulointerstitial injury
can be built (Fig. 1). A local insult (immunological, hypoxic, toxic,
mechanical, etc.) activates de novo chemokine production by, for
example: (a) glomerular or peritubular capillary endothelial cells;
(b) glomerular or tubular epithelial cells; (c) mesangial or inter-
stitial cells. Other pro- or anti-inflammatory cytokines or media-
tors may be generated concomitantly. Local activation of platelets
may result in release of preformed chemokines (RANTES, MIP-
la, PF4, PBP) and cytokines (such as PDGF) from the platelets
directly propagating the inflammatory cascade at the endothelial
surface. The chemokines will form a gradient. Once chemokines
reach the capillary endothelial surface they will activate circulat-
ing leukocytes bearing the respective surface receptors. This will
induce interaction of the leukocyte integrin with the adhesion
molecules of the immunoglobulin superfamily (such as ICAM-1
and VCAM-1) on endothelial, mesangial and interstitial cells and
result in local attachment of the leukocytes. The leukocytes will
then transmigrate along the chemokine gradient to the original
site of injury and enhance chemokine production at a subendo-
thelial, mesangial, interstitial or epithelial location. The transmi-
gration involves activation of metalloprotemnases and plasmin—
potentially mediated in part by chemokines—to facilitate
diapedesis across basement membranes and extracellular matrix.
In this process matrix-bound growth factors, such as TGF-p, and
fibroblast growth factors may be activated. These, together with
other mediators produced at the original site of tissue injury, will
further activate the infiltrating leukocytes. The activation of the
leukocytes will initiate their effector functions (such as respiratory
burst, phagocytosis of immune complexes, release of hydrolases,
removal of matrix, cell debris, and apoptotic cells). Furthermore,
the activated leukocytes will produce additional mediators (such
as ROS, PAF, leukotrienes, prostaglandins), chemokines, and
cytokines (such as IL-113, TNF-a) that will result in an amplifica-
tion loop and further leukocyte recruitment. At this point it is
possible that infiltrating PMN initially attracted by local IL-8 may
now generate monocyte directed chemokines [108] and thus
attract monocyte-macrophages. Further along in the inflamma-
tory process, T-cell-specific chemokines might be generated by
infiltrating or resident cells and cause a late influx of T-cells which
become activated, produce chemokines and factors leading to
propagation and amplification of the inflammatory cascade.
A considerable amount of experimental data supports the
model up to the point of tissue infiltration. Much less is known,
however, about the factors that control the type of chemokine
generated and what eventually terminates chemokine and cyto-
kine production and down-regulates the inflammatory response.
The latter will determine the eventual outcome of the disease
process that is, healing or chronic inflammation resulting in
fibrosis.
In this context we would like to raise some questions that need
to be adressed in order to better understand chemokine function
in renal diseases:
(A) Which factors limit the initial chemokine expression at the
site of injury? Is it the short-lasting effect of the stimuli on
chemokine mRNA transcription together with the brief half-life
of most chemokine mRNAs? Is there down-regulation of chemo-
kine activation upon continued stimulation, and if so, what is the
molecular basis?
(B) What determines the pattern of specific chemokines pro-
duced at a given time point in the inflammatory process? Many
stimuli, such as IL-i, TNF-a, immune complexes or ROS will
cause production of a number of ehemokines by cultured cells and
leukocytes. However, in vivo only some chemokines are expressed
at a given time point and a restricted repertoire of inflammatory
cells is recruited. Furthermore, in vivo chemokine expression
seems to follow a certain time course, that is, different chemokines
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may be generated sequentially. Does this involve a cell-type
specific temporal pattern of chemokine expression? Could che-
mokine generation be more restricted in vivo because of cell-cell
or cell-matrix interactions or because of a specific local milieu that
is a composition of various stimulatory and inhibitory mediators?
Another factor that could influence the specifity of the cell
inflitrate could be the expression pattern for the chemokine
receptors on the leukocytes, which might also be influenced by
inflammatory mediators.
Some of these questions may also be relvant for the interaction
of infiltrating inflammatory cells with the local resident cells. For
example, could the engagement of leukocyte integrins with
ICAM-1 or VCAM-1 on the resident cells terminate or amplify
the chemokine production or alter its pattern from a previously
PMN-specific one to one directed towards monocytes or T cells?
(C) Do chemokines fulfill different functions as the inflamma-
tory process progresses? For example, can a massive local chemo-
kine production as it may occur at the site of an inflammatory
infiltrate with its amplification loops, eventually result in a down-
regulation of the response of the target leukocytes, similar to what
is observed with systemic administration of chemokines? Can high
concentrations of chemokines, perhaps in combination with other
local mediators, influence apoptosis?
(D) What is the role of chemokines in repair processes, in
chronic inflammatory processes and in fibrosis? For example,
chemokines may influence metalloproteinases and some C-X-C
chemokines appear to have angiogenic and antifibrogenic capa-
bilities.
These are intriguing questions that need to be addressed in
order to clarify our picture of the role of chemokines in renal
diseases. Answers to these questions will require a multipronged
approach including studies on signal transduction and gene
regulation at the molecular level in cultured cells. Potentially new
functions of chemokines (such as angiogenesis and cell survival)
can initially be investigated in vitro and then have to be verified in
vivo. Additional detailed time course studies and investigations on
the cellular sources for chemokines have to be performed in
experimental models of renal diseases using immunohistology and
in situ hybridization. The question of which specific chemokine is
produced in response to a defined injury should also be clarified
by these experiments. Furthermore, interference with chemokine
generation and function needs to be attempted. The contribution,
if any, of chemokines to chronic fibrosing processes should be
evaluated by a comparable approach. Generation of chemokine
and chemokine receptor knockout mice may provide hints for new
chemokine functions. Finally, complementary evaluation of hu-
man kidney biopsy material must validate the experimental find-
ings.
Since multiple roles for chemokincs at various stages of inflam-
matory processes have been described (Fig. 1), one can envision
many levels at which to interrupt the various actions of the
chemokines to affect inflammation [41, 109]. For example, the
expression of chemokines by fibroblasts, endothelial and epithelial
cells induced by proinflammatory cytokines may be suppressed by
soluble TNF receptor or IL-i receptor antagonists [1101. Glu-
cocorticoids inhibit transcription of several chemokine genes
including IL-8 [1111, MCP-1 [112] and RANTES [1131. Agents
that interfere with matrix and surface binding of chcmokines such
as heparin may influence chemokine effects [1141. Humanized
neutralizing antibodies or competitive inhibitors directed against
chemokines and/or their receptors may be effective [115, 1161.
Finally, it may be possible to develop selective inhibitors of the
signal transduction pathways downstream of the chemokine re-
ceptors. Given the apparent redundancy of function described for
many of these molecules, it is unclear whether the suppression of
a single chemokine will be therapeutically useful. It is also unclear
whether such agents will have deleterious side effects such as
nonspecific immunosuppression. Nonetheless, influencing chemo-
kine generation and action may turn out to be of considerable
therapeutic benefit.
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Note added in proof
After submission of the manuscript several important papers have been
published. A new human chemokine receptor (CXCR-3) specific for IP-lO
and Mig was identified [117]. The lymphocyte chemoattractant SDF-1 has
been shown to act as a ligand for the chemokine receptor CXCR-4
(LESTR/fusin). This receptor can function as an ently cofactor for T cell
line-tropic isolates of HIV-1 [118, 119, 120]. A deletion has been found in
the CCR-5 gene which appears to confer resistance to HIV-1 infection in
homozygous individuals [121, 1221.
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